A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension

Administered By

Awarded By

Contributors

Start/End

  • February 21, 2020 - November 30, 2021